JUN 13, 2020 12:14 PM PDT

Examining Cancers Effect on the Immune System for Prognostic Use

WRITTEN BY: Jasper Cantrell

Most think of cancer in the context of where it is on the body like breast or pancreatic cancer. There are several more ways of broadly classifying cancers, however. One such way is how cancer can influence the environment around them, in particular how it affects the immune system. By examining the tumor immune microenvironment (TIME), a doctor or researcher could obtain valuable prognostic information. Three general TIME groups have been identified. An anti-tumor TIME group characterized by a relatively high number of anti-cancer immune cells, a pro-tumor TIME group characterized by a lack of anti-tumor immune cells and a high number of immune-suppressing cells and a third group is an immune-absent group characterized by the lack of an immune response overall.

A team from the Research Center of Borstel in Germany took an interest in these TIME groups and began an investigation. Their goal was to identify any genes or other factors that were unique to each TIME group. They pulled the data of 155 head and neck squamous cell carcinomas (HNSCC) patients from The Cancer Genome Atlas (TCGA) and began their investigations.

The team defined TIME groups based on their expression of genes related to the cytotoxic T-cell response. An immune-activated TIME group would have elevated expression, an immune-suppressed TIME group would have lower expression, and an immune absent TIME group would have a lower expression of all immune-related genes. Examining the patient data, the immune-activated TIME group had a higher overall survival rate over the other two groups. Patients with late-stage tumors were far more likely to be in the immune-suppressed TIME group than any other group. They also found a tumor’s histology, or a tumor’s structure, was more likely to be similar amongst patients of the same group.

The team then began to look at possible gene mutations in each group that were unique. The standout genes were TP53, which had a strong correlation with the immune absent TIME group, and EP300, which correlated with the immune-activated TIME group. They decided to follow up on EP300.  A quick analysis of TCGA data showed that EP300 mutations correlated with the immune-activated TIME group of gastric, prostate, and esophageal squamous cell carcinomas as well as HNSCC. EP300 is also known to increase the expression of glycolytic genes. Glycolysis is an inefficient energy production method used when oxygen is not available. It also produces lactic acid, which can act as a suppressor of the immune system. Mutations in EP300 would reduce the amount of lactic acid in tumor cells, and promote an anti-tumor TIME.

The group’s efforts revealed that the TIME of a tumor might indeed have prognostic value. Unique genetic biomarkers for TIME were scarce, unfortunately. TP53 is already linked to the regulation of the anti-tumor immune response, but EP300 was less understood. In silico analyses showed it was strongly linked to the anti-cancer immune response, with mutations in EP300 resulting in an immune-active TIME. The study of alternative pan-cancer types may one day allow for a better understanding of why certain drugs and therapies work on some cancer subtypes but not others. TIME grouping has promise, but much more research is needed before it can be considered a strong argument one way or another.

Sources: Nature, Nature Video
 

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
MAY 28, 2020
Cancer
Oncologists need more training on how to deliver bad news
MAY 28, 2020
Oncologists need more training on how to deliver bad news
A commentary published earlier this spring in the Journal of Clinical Oncology urges for improved training for medical p ...
JUN 23, 2020
Cancer
Why are certain people more vulnerable to carcinogens?
JUN 23, 2020
Why are certain people more vulnerable to carcinogens?
A study from the University of Hawaii Cancer Center entitled, "Tumour predisposition and cancer syndromes as models ...
JUL 10, 2020
Cancer
Researching New RNA Biomarkers for Liver Cancer
JUL 10, 2020
Researching New RNA Biomarkers for Liver Cancer
The most important part of cancer treatment is the first step, diagnosis. Many cancers can lie dormant for years, reachi ...
JUL 14, 2020
Drug Discovery & Development
How Cancer Cells Influence Drug Responses
JUL 14, 2020
How Cancer Cells Influence Drug Responses
When studying a large number of brain samples, researchers were able to characterize how changes in cells influence drug ...
AUG 03, 2020
Cancer
Improving Diagnostics in Breast Cancer
AUG 03, 2020
Improving Diagnostics in Breast Cancer
Diagnostics is one of the essential tools in a physician’s toolkit. A good diagnostic test can identify whether a ...
AUG 03, 2020
Cancer
New research on fusion proteins that may help young patients with synovial sarcoma
AUG 03, 2020
New research on fusion proteins that may help young patients with synovial sarcoma
New research is published by scientists at Dana-Farber Cancer Institute have discovered new information that may help pa ...
Loading Comments...